More news – Page 8
-
NewsOrsellinic acid produced in E. coli for first time
Study findings could provide an alternative production platform for rhododendron-derived drugs with potent anticancer and anti-HIV properties.
-
NewsRois appoints Kimberlee Steele as Chief Commercial Officer
She joins the Madrid-headquartered contract development and manufacturing organisation from SHL Medical.
-
NewsSanofi’s Beyfortus shows infant benefit beyond first RSV season
The biologic enabled a significant reduction in RSV-related hospitalisations in infants through a second RSV season.
-
NewsNovartis bolsters the case for Vanrafia’s full approvals in IgA nephropathy
Phase III results will support the firm’s planned filings for traditional approvals later in 2026, following last year’s US and China accelerated approvals.
-
NewsAmgen wins new European approval for Uplizna in generalised myasthenia gravis
The EC decision clears a new first-in-class approach to manage the rare autoimmune condition.
-
NewsFormulation research offers step towards digital tablet design
Findings could lead to more robust tablet design and a minimising of the materials used, such as active pharmaceutical ingredients (APIs).
-
NewsSanofi selects Dr Belén Garijo as new CEO
The company veteran will return to lead the pharma firm, taking over from Paul Hudson.
-
NewsRottendorf and Corealis collaborate on OSD manufacturing
The two CDMOs sign an alliance to offer an integrated early-development offering and accelerated commercial pathway.
-
NewsDr Veit Bergendahl to join Rentschler Biopharma as Chief Operating Officer
New operations lead brings over twenty years of biopharma experience to the CDMO’s Laupheim and Milford sites.
-
NewsFujifilm Biotechnologies inaugurates expanded £400m UK biomanufacturing site
The CDMO’s investment in the North-East based site expansion supports UK production of medicines and vaccines.
-
NewsFresenius Kabi and Phlow onshore US epinephrine manufacturing
The collaboration covers the essential medicine's active pharmaceutical ingredients (APIs) and finished doses.
-
NewsEMA opens consultation for Annex 15 GMP guidelines
Proposal guideline by EMA anticipated to replace Eudralex Volume 4: Annex 15 Qualification and validation.
-
NewsLilly acquires CAR-T therapy biotech Orna Therapeutics for $2.4bn
Agreement with Orna Therapeutics includes potential best-in-class, immune-targeting in vivo CAR-T therapies.
-
NewsBMS partners with Evinova to strengthen clinical development using AI
Aims to shorten medicine development timelines, improve likelihood of trial success and reduce clinical trial costs.
-
NewsRoche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis
New Phase III data presented at ACRIMS suggests the oral BTK inhibitor could become a first-in-class multiple sclerosis therapy.
-
NewsTitanium dioxide-free drotaverine hydrochloride tablets developed
Study findings indicate an alternative coating that would comply with potential future regulation against use of titanium dioxide as a pharmaceutical excipient.
-
NewsGSK’s Nucala green lit for COPD in expanded EU approval
The EC's decision opens up the monthly biologic for use by COPD patients with an eosinophils phenotype.
-
NewsCrystallisation research could enhance API drug production
Thermodynamic framework supports rapid assessment of solvents during active pharmaceutical ingredient (API) manufacturing.
-
NewsAstraZeneca’s Imfinzi plus chemotherapy earns CHMP nod in gastric cancer
If approved, the regimen would become the first immunotherapy-based perioperative therapy for adults with early gastric and gastroesophageal cancers in Europe.
-
NewsNMD Pharma will ‘accelerate’ rare disease drug ignaseclant despite endpoint miss
But phase II data of the small molecule inhibitor for Charcot-Marie-Tooth disease Types 1 and 2 did show it meeting secondary endpoints for functional improvements.